razoxane has been researched along with epirubicin in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 8 (32.00) | 18.2507 |
| 2000's | 12 (48.00) | 29.6817 |
| 2010's | 4 (16.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Alderton, PM; Green, MD; Gross, J | 1 |
| Dardir, M; Ferrans, VJ; Herman, EH | 1 |
| Bastholt, L; Gjedde, SB; Jakobsen, P; Mirza, MR; Mouridsen, HT; Rose, C; Sørensen, B | 2 |
| Basser, RL; Cebon, J; Duggan, G; Green, MD; Mihaly, G; Rosenthal, MA; Sobol, MM | 1 |
| Bellina, RC; Bruzzi, P; Carnino, F; Conte, PF; Cyrus, P; Del Mastro, L; Gallo, L; Garrone, O; Guelfi, M; Lionetto, R; Michelotti, A; Molea, N; Pronzato, P; Rosso, R; Testore, F; Tibaldi, C; Venturini, M; Vinke, J | 1 |
| Conti, F; Di Lauro, K; Ferraironi, A; Giannarelli, D; Lopez, M; Maini, CL; Paoletti, G; Sciuto, R; Vici, P | 1 |
| Lopez, M; Vici, P | 1 |
| Bramwell, V; Moran, LA; Seymour, L | 1 |
| Bengala, C; Carnino, F; Conte, P; Del Mastro, L; Gallo, L; Lionetto, R; Michelotti, A; Montanaro, E; Rosso, R; Tibaldi, C; Venturini, M | 1 |
| Bos, AM; van der Graaf, WT; Willemse, PH | 1 |
| Budman, DR; Calabro, A | 1 |
| Jensen, JN; Langer, SW; Lock-Andersen, J; Mejer, J | 1 |
| Baioni, M; Ballardini, M; De Giorgi, U; Ferrari, E; Marangolo, M; Minzi, MR; Rosti, G; Zaniboni, A; Zornetta, L | 1 |
| Arsovski, O; Debourdeau, P; Gligorov, J; Lotz, JP | 1 |
| Carpi, A; Cecconi, N; Cervetti, G; Franzoni, F; Galetta, F; Petrini, M; Santoro, G | 1 |
| De Giorgi, U; Emiliani, E; Frassineti, L; Giannini, M; Giovannini, N; Kopf, B; Marangolo, M; Palazzi, S; Rosti, G; Zumaglini, F | 1 |
| Brouwer, RE; Uges, JW; Vollaard, AM; Wilms, EB | 1 |
| Bárdi, E; Bobok, I; Kappelmayer, J; Kiss, C; V Oláh, A | 1 |
| Bosso, G; Ceste, M; de Conciliis, E; Ferrero, G; Ferro, S; Giaretto, L; Lanfranco, C; Manfredi, R; Miglietta, L; Milanese, S; Parello, G; Simoni, C; Testore, F | 1 |
| Aloi, C; Altieri, P; Barsotti, A; Brunelli, C; Ghigliotti, G; Pronzato, P; Spallarossa, P | 1 |
| Antonelli, A; Carpi, A; Cervetti, G; Fallahi, P; Franzoni, F; Galetta, F; Petrini, M; Regoli, F; Santoro, G; Tocchini, L | 1 |
| Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C | 1 |
| Hao, XM; Li, WJ; Wang, P; Zhang, J; Zhang, S; Zhang, XB | 1 |
2 review(s) available for razoxane and epirubicin
| Article | Year |
|---|---|
European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Epirubicin; Europe; Heart Diseases; Humans; Razoxane | 1998 |
[Cardiac prevention: the oncologic point of view].
Topics: Age Factors; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Heart; Heart Diseases; Humans; Liposomes; Paclitaxel; Razoxane; Risk Factors; Trastuzumab | 2004 |
11 trial(s) available for razoxane and epirubicin
| Article | Year |
|---|---|
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatography, High Pressure Liquid; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Fluorouracil; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Razoxane; Tamoxifen | 1994 |
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
Topics: Adult; Aged; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasms; Razoxane; Stomatitis; Vomiting | 1994 |
The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Razoxane; Tamoxifen | 1994 |
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Razoxane | 1996 |
Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Drug Monitoring; Epirubicin; Female; Heart; Heart Rate; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radionuclide Imaging; Razoxane; Sarcoma; Ventricular Function, Left | 1998 |
Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Epirubicin; Female; Heart Failure; Humans; Injections, Intravenous; Middle Aged; Razoxane; Treatment Outcome; Ventricular Dysfunction, Left | 2000 |
High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer.
Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Middle Aged; Neutropenia; Paclitaxel; Razoxane; Recombinant Proteins | 2003 |
Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients.
Topics: Antibiotics, Antineoplastic; Arrhythmias, Cardiac; Cardiovascular Agents; Drug Therapy, Combination; Electrocardiography; Epirubicin; Female; Heart Conduction System; Humans; Lymphoma, Non-Hodgkin; Male; Razoxane; Time Factors | 2005 |
Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Epirubicin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Pneumonitis; Radiodermatitis; Razoxane; Recombinant Proteins | 2006 |
In vitro and in vivo study on the antioxidant activity of dexrazoxane.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bleomycin; Chromans; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Free Radical Scavengers; Glutathione; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisone; Razoxane; Time Factors; Uric Acid; Vincristine | 2010 |
[Protective effect of dexrazoxane on cardiotoxicity in breast cancer patients who received anthracycline-containing chemotherapy].
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Bone Marrow; Breast Neoplasms; Cardiovascular Agents; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Heart Rate; Humans; Leukocyte Count; Middle Aged; Natriuretic Peptide, Brain; Neutrophils; Razoxane; Stroke Volume; Young Adult | 2013 |
12 other study(ies) available for razoxane and epirubicin
| Article | Year |
|---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
Topics: Animals; Doxorubicin; Epirubicin; Female; Heart; Mice; Mice, Inbred BALB C; Mitoxantrone; Myocardium; Premedication; Random Allocation; Razoxane | 1992 |
Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Drug Evaluation, Preclinical; Drug Interactions; Epirubicin; Heart; Kidney; Male; Microscopy, Electron; Myocardium; Piperazines; Rats; Rats, Inbred SHR; Razoxane; Stereoisomerism | 1989 |
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Epirubicin; Evidence-Based Medicine; Female; Heart; Heart Failure; Humans; Neoplasms; Odds Ratio; Randomized Controlled Trials as Topic; Razoxane; Time Factors; Treatment Outcome | 1999 |
A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cryotherapy; Cyclophosphamide; Dimethyl Sulfoxide; Edema; Enzyme Inhibitors; Epirubicin; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorouracil; Free Radical Scavengers; Hand; Humans; Hydrocortisone; Infusions, Intravenous; Iron Chelating Agents; Pain; Pain Management; Razoxane; Ulcer | 2001 |
In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disulfiram; Docetaxel; Drug Interactions; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epirubicin; Female; Humans; Paclitaxel; Razoxane; Taxoids; Tretinoin; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2002 |
Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Epirubicin; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Razoxane | 2003 |
Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Pleural Cavity; Pleural Effusion; Razoxane; Treatment Outcome | 2006 |
Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer.
Topics: Acetylglucosaminidase; Adolescent; Adult; Albuminuria; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Child; Child, Preschool; Creatinine; Daunorubicin; Doxorubicin; Epirubicin; Female; Humans; Idarubicin; Infant; Kidney Diseases; Kidney Tubules, Proximal; Lymphoma, Non-Hodgkin; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Retrospective Studies | 2007 |
Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Electrocardiography; Epirubicin; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Life Expectancy; Middle Aged; Neoplasm Metastasis; Razoxane; Retrospective Studies | 2008 |
Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane.
Topics: Actins; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Cardiotonic Agents; Cell Culture Techniques; Cell Death; Cell Line; Dose-Response Relationship, Drug; Drug Synergism; Epirubicin; Glycoproteins; Immunoblotting; Membrane Potential, Mitochondrial; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Razoxane; Receptor, ErbB-2 | 2010 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine | 2011 |